Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4P8YO
|
|||
| Drug Name |
AB023
|
|||
| Drug Type |
Antibody
|
|||
| Indication | End-stage renal disease [ICD-11: GB61.5; ICD-10: N18.5] | Phase 1 | [1] | |
| Company |
Aronora
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor XI (F11) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03097341) Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.